Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Antibodies and venom peptides: new modalities for ion channels.

Wulff H, Christophersen P, Colussi P, Chandy KG, Yarov-Yarovoy V.

Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8. Review.

2.

The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells.

Pillozzi S, D'Amico M, Bartoli G, Gasparoli L, Petroni G, Crociani O, Marzo T, Guerriero A, Messori L, Severi M, Udisti R, Wulff H, Chandy KG, Becchetti A, Arcangeli A.

Br J Cancer. 2018 Jan;118(2):200-212. doi: 10.1038/bjc.2017.392. Epub 2017 Nov 21.

3.

A Non-invasive Way to Isolate and Phenotype Cells from the Conjunctiva.

Bose T, Hou A, Lee R, Tong L, Chandy KG.

J Vis Exp. 2017 Jul 5;(125). doi: 10.3791/55591.

4.

Venom-derived peptide inhibitors of voltage-gated potassium channels.

Norton RS, Chandy KG.

Neuropharmacology. 2017 Dec;127:124-138. doi: 10.1016/j.neuropharm.2017.07.002. Epub 2017 Jul 5. Review.

PMID:
28689025
5.

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue.

Hou A, Bose T, Chandy KG, Tong L.

J Vis Exp. 2017 Jun 7;(124). doi: 10.3791/55592.

6.

Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease.

Chandy KG, Norton RS.

Curr Opin Chem Biol. 2017 Jun;38:97-107. doi: 10.1016/j.cbpa.2017.02.015. Epub 2017 Apr 14. Review.

PMID:
28412597
7.

Tissue resident memory T cells in the human conjunctiva and immune signatures in human dry eye disease.

Bose T, Lee R, Hou A, Tong L, Chandy KG.

Sci Rep. 2017 Mar 27;7:45312. doi: 10.1038/srep45312.

8.

International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels.

Kaczmarek LK, Aldrich RW, Chandy KG, Grissmer S, Wei AD, Wulff H.

Pharmacol Rev. 2017 Jan;69(1):1-11. doi: 10.1124/pr.116.012864. Epub 2016 Nov 15. Review.

PMID:
28267675
9.

Immunology: Channelling potassium to fight cancer.

Chandy KG, Norton RS.

Nature. 2016 Sep 22;537(7621):497-499. doi: 10.1038/nature19467. Epub 2016 Sep 14. No abstract available.

PMID:
27626384
10.

Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG.

FASEB J. 2014 Sep;28(9):3952-64. doi: 10.1096/fj.14-251967. Epub 2014 Jun 2.

11.

Blockade of Kv1.3 channels ameliorates radiation-induced brain injury.

Peng Y, Lu K, Li Z, Zhao Y, Wang Y, Hu B, Xu P, Shi X, Zhou B, Pennington M, Chandy KG, Tang Y.

Neuro Oncol. 2014 Apr;16(4):528-39. doi: 10.1093/neuonc/not221. Epub 2013 Dec 4.

12.

Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics.

Lioudyno MI, Birch AM, Tanaka BS, Sokolov Y, Goldin AL, Chandy KG, Hall JE, Alkire MT.

J Neurosci. 2013 Oct 9;33(41):16310-22. doi: 10.1523/JNEUROSCI.0344-13.2013.

13.

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.

Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2239-48. doi: 10.1073/pnas.1221206110. Epub 2013 May 31.

14.

Intracellular trafficking of the KV1.3 potassium channel is regulated by the prodomain of a matrix metalloprotease.

Nguyen HM, Galea CA, Schmunk G, Smith BJ, Edwards RA, Norton RS, Chandy KG.

J Biol Chem. 2013 Mar 1;288(9):6451-64. doi: 10.1074/jbc.M112.421495. Epub 2013 Jan 8.

15.

Modulation of voltage-gated K+ channels by the sodium channel β1 subunit.

Nguyen HM, Miyazaki H, Hoshi N, Smith BJ, Nukina N, Goldin AL, Chandy KG.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18577-82. doi: 10.1073/pnas.1209142109. Epub 2012 Oct 22.

16.

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP.

J Pharmacol Exp Ther. 2012 Sep;342(3):642-53. doi: 10.1124/jpet.112.191890. Epub 2012 May 25.

17.

Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.

Gocke AR, Lebson LA, Grishkan IV, Hu L, Nguyen HM, Whartenby KA, Chandy KG, Calabresi PA.

J Immunol. 2012 Jun 15;188(12):5877-86. doi: 10.4049/jimmunol.1103095. Epub 2012 May 11.

18.

Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells.

Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E, Szabò I.

EMBO Mol Med. 2012 Jul;4(7):577-93. doi: 10.1002/emmm.201200235. Epub 2012 Apr 11.

19.

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG.

Toxicon. 2012 Mar 15;59(4):529-46. doi: 10.1016/j.toxicon.2011.07.016. Epub 2011 Aug 12. Review.

20.

Therapeutic potential of peptide toxins that target ion channels.

Beraud E, Chandy KG.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):322-42. Review.

PMID:
21745182
21.

18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies.

Garcia A, Mirbolooki MR, Constantinescu C, Pan ML, Sevrioukov E, Milne N, Wang PH, Lakey J, Chandy KG, Mukherjee J.

J Nucl Med. 2011 Jul;52(7):1125-32. doi: 10.2967/jnumed.111.088583. Epub 2011 Jun 16.

22.

Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.

Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, Beeton C, Torossian S, Tatarian GG, Lee SU, Lau K, Walker E, Siminovitch KA, Chandy KG, Yu Z, Dennis JW, Demetriou M.

Nat Commun. 2011;2:334. doi: 10.1038/ncomms1333.

23.

Potassium channel modulation by a toxin domain in matrix metalloprotease 23.

Rangaraju S, Khoo KK, Feng ZP, Crossley G, Nugent D, Khaytin I, Chi V, Pham C, Calabresi P, Pennington MW, Norton RS, Chandy KG.

J Biol Chem. 2010 Mar 19;285(12):9124-36. doi: 10.1074/jbc.M109.071266. Epub 2009 Dec 4.

24.

The functional network of ion channels in T lymphocytes.

Cahalan MD, Chandy KG.

Immunol Rev. 2009 Sep;231(1):59-87. doi: 10.1111/j.1600-065X.2009.00816.x. Review.

25.

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.

Rangaraju S, Chi V, Pennington MW, Chandy KG.

Expert Opin Ther Targets. 2009 Aug;13(8):909-24. doi: 10.1517/14728220903018957. Review.

PMID:
19538097
26.

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, Dixon C, Chauhan S, Orzel A, Inoue T, Hu X, Moore RV, Norton RS, Chandy KG.

Mol Pharmacol. 2009 Apr;75(4):762-73. doi: 10.1124/mol.108.052704. Epub 2009 Jan 2.

27.

Imaging effector memory T cells in the ear after induction of adoptive DTH.

Matheu MP, Beeton C, Parker I, Chandy KG, D Cahalan M.

J Vis Exp. 2008 Aug 14;(18). pii: 907. doi: 10.3791/907.

28.

Induction and monitoring of active delayed type hypersensitivity (DTH) in rats.

Beeton C, Chandy KG.

J Vis Exp. 2007;(6):237. doi: 10.3791/237. Epub 2007 Jul 19.

29.

Drawing blood from rats through the saphenous vein and by cardiac puncture.

Beeton C, Garcia A, Chandy KG.

J Vis Exp. 2007;(7):266. doi: 10.3791/266. Epub 2007 Aug 23.

30.

Enrichment of NK cells from human blood with the RosetteSep kit from StemCell technologies.

Beeton C, Chandy KG.

J Vis Exp. 2007;(8):326. doi: 10.3791/326. Epub 2007 Oct 1.

31.

Immunohistochemistry: paraffin sections using the Vectastain ABC kit from vector labs.

Chi V, Chandy KG.

J Vis Exp. 2007;(8):308. doi: 10.3791/308. Epub 2007 Oct 1.

32.

Isolation of mononuclear cells from the central nervous system of rats with EAE.

Beeton C, Chandy KG.

J Vis Exp. 2007;(10):527. doi: 10.3791/527. Epub 2007 Dec 4.

33.

Preparing T cell growth factor from rat splenocytes.

Beeton C, Chandy KG.

J Vis Exp. 2007;(10):402. doi: 10.3791/402. Epub 2007 Oct 31.

34.

Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis.

Beeton C, Garcia A, Chandy KG.

J Vis Exp. 2007;(5):224. doi: 10.3791/224. Epub 2007 Jul 4.

35.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

36.

Mouse adrenal chromaffin cell isolation.

Kolski-Andreaco A, Cai H, Currle DS, Chandy KG, Chow RH.

J Vis Exp. 2007 Jan 5;(2):129. doi: 10.3791/129.

37.

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.

Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, Melvin JE, Pratt PF, Hatoum OA, Gutterman DD, Harder DR, Miura H.

J Clin Invest. 2008 Sep;118(9):3025-37. doi: 10.1172/JCI30836.

38.

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.

Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS.

J Biol Chem. 2008 Jan 11;283(2):988-97. Epub 2007 Nov 5.

39.

Induction and monitoring of adoptive delayed-type hypersensitivity in rats.

Beeton C, Chandy KG.

J Vis Exp. 2007 Oct 1;(8). pii: 325. doi: 10.3791/325.

40.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9. Epub 2006 Nov 6.

41.

International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.

Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X.

Pharmacol Rev. 2005 Dec;57(4):473-508. Review. No abstract available.

PMID:
16382104
42.

International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels.

Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H.

Pharmacol Rev. 2005 Dec;57(4):463-72. Review. No abstract available.

PMID:
16382103
43.

Potassium channels, memory T cells, and multiple sclerosis.

Beeton C, Chandy KG.

Neuroscientist. 2005 Dec;11(6):550-62. Review.

PMID:
16282596
44.

The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.

Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11094-9. Epub 2005 Jul 25.

45.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.

46.

K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.

Wulff H, Knaus HG, Pennington M, Chandy KG.

J Immunol. 2004 Jul 15;173(2):776-86.

47.

Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.

Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, Chandy KG.

Mol Pharmacol. 2004 Jun;65(6):1364-74.

PMID:
15155830
48.

K+ channels as targets for specific immunomodulation.

Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD.

Trends Pharmacol Sci. 2004 May;25(5):280-9. Review.

49.

SKCa channels mediate the medium but not the slow calcium-activated afterhyperpolarization in cortical neurons.

Villalobos C, Shakkottai VG, Chandy KG, Michelhaugh SK, Andrade R.

J Neurosci. 2004 Apr 7;24(14):3537-42.

50.

Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia.

Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG.

J Clin Invest. 2004 Feb;113(4):582-90.

Supplemental Content

Loading ...
Support Center